Lantern Pharma (NASDAQ: LTRN) is a clinical stage oncology company leveraging A.I., Machine Learning and genomics to develop targeted small molecule cancer drugs. Lantern's RADR A.I. engine is the world's largest oncology focused A.I. drug discovery and development platform. With three drugs in active clinical development: Two in phase 2 and one in pre-clinical. Each precisely targeted at a genetically-defined patient population. The company is fully funded through at least the end of 2022 and anticipates adding at least one new drug target to the pipeline each year.
Ticker:
LTRN
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Oncology
Lead Product in Development:
LP100
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
